MediXall Group
- Home ›
- US ›
- Healthcare
MediXall Group, Inc. operates as a healthcare incubator for development-stage healthcare technology companies in the United States. The last earnings update was 17 days ago. More info.
Add to Portfolio Compare Print
- MediXall Group has significant price volatility in the past 3 months.
MDXL Share Price and Events
7 Day Returns
1 Year Returns
MDXL Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| MediXall Group (MDXL) | 50% | 50% | - | -30% | - | - |
| US Healthcare Services | 0.6% | 4.2% | 14.7% | 24.3% | 77.5% | 66% |
| US Market | 0.5% | 0.2% | 1.1% | 0.8% | 37.4% | 37.5% |
1 Year Return vs Industry and Market
- MDXL underperformed the Healthcare Services industry which returned 24.3% over the past year.
- MDXL underperformed the Market in United States of America which returned 0.8% over the past year.
MDXL Value
Is MediXall Group undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for MediXall Group. This is due to cash flow or dividend data being unavailable. The share price is $2.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for MediXall Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
MediXall Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-0.04 |
| OTCPK:MDXL Share Price ** | OTCPK (2019-06-10) in USD | $2.1 |
| United States of America Healthcare Services Industry PE Ratio | Median Figure of 13 Publicly-Listed Healthcare Services Companies | 52.35x |
| United States of America Market PE Ratio | Median Figure of 3,091 Publicly-Listed Companies | 17.68x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of MediXall Group.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = OTCPK:MDXL Share Price ÷ EPS (both in USD) = 2.1 ÷ -0.04 |
-52.05x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- MediXall Group is loss making, we can't compare its value to the US Healthcare Services industry average.
- MediXall Group is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
MediXall Group's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -52.05x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| United States of America Healthcare Services Industry PEG Ratio | Median Figure of 12 Publicly-Listed Healthcare Services Companies | 2.42x |
| United States of America Market PEG Ratio | Median Figure of 2,125 Publicly-Listed Companies | 1.52x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for MediXall Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
MediXall Group's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $0.01 |
| OTCPK:MDXL Share Price * | OTCPK (2019-06-10) in USD | $2.1 |
| United States of America Healthcare Services Industry PB Ratio | Median Figure of 36 Publicly-Listed Healthcare Services Companies | 5.06x |
| United States of America Market PB Ratio | Median Figure of 5,244 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = OTCPK:MDXL Share Price ÷ Book Value per Share (both in USD) = 2.1 ÷ 0.01 |
285.6x |
* Primary Listing of MediXall Group.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- MediXall Group is overvalued based on assets compared to the US Healthcare Services industry average.
Value checks
We assess MediXall Group's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check) MediXall Group has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
MDXL Future Performance
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MediXall Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare MediXall Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare MediXall Group's earnings growth to the United States of America market average as no estimate data is available.
- Unable to compare MediXall Group's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| United States of America Healthcare Services Industry Earnings Growth Rate | Market Cap Weighted Average | 23.8% |
| United States of America Healthcare Services Industry Revenue Growth Rate | Market Cap Weighted Average | 11.8% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 0 | -2 | -3 |
| 2018-12-31 | 0 | -2 | -3 |
| 2018-09-30 | 0 | -2 | -3 |
| 2018-06-30 | 0 | -2 | -3 |
| 2018-03-31 | 0 | -2 | -2 |
| 2017-12-31 | 0 | -2 | -2 |
| 2017-09-30 | 0 | -2 | -1 |
| 2017-06-30 | -2 | -1 | |
| 2017-03-31 | -1 | -1 | |
| 2016-12-31 | -1 | -1 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from MediXall Group Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -0.04 |
| 2018-12-31 | -0.05 |
| 2018-09-30 | -0.05 |
| 2018-06-30 | -0.04 |
| 2018-03-31 | -0.04 |
| 2017-12-31 | -0.03 |
| 2017-09-30 | -0.03 |
| 2017-06-30 | -0.05 |
| 2017-03-31 | -0.07 |
| 2016-12-31 | -0.25 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if MediXall Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess MediXall Group's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
MediXall Group has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
MDXL Past Performance
How has MediXall Group performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- MediXall Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare MediXall Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare MediXall Group's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
All data from MediXall Group Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 0.00 | -2.72 | 1.43 | |
| 2018-12-31 | 0.00 | -2.98 | 1.19 | |
| 2018-09-30 | 0.01 | -2.90 | 1.14 | |
| 2018-06-30 | 0.02 | -2.50 | 0.91 | |
| 2018-03-31 | 0.02 | -2.18 | 0.72 | |
| 2017-12-31 | 0.02 | -1.56 | 0.74 | |
| 2017-09-30 | 0.01 | -1.34 | 0.70 | |
| 2017-06-30 | -1.23 | 0.70 | ||
| 2017-03-31 | -0.99 | 0.67 | ||
| 2016-12-31 | -0.66 | 0.47 | ||
| 2015-12-31 | -0.35 | 0.24 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if MediXall Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if MediXall Group has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if MediXall Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess MediXall Group's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
MediXall Group has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
MDXL Health
How is MediXall Group's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up MediXall Group's finances.
The net worth of a company is the difference between its assets and liabilities.
- MediXall Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- MediXall Group's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- MediXall Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from MediXall Group Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 0.53 | 0.16 | 0.06 |
| 2018-12-31 | 0.54 | 0.00 | 0.20 |
| 2018-09-30 | -0.05 | 0.00 | 0.02 |
| 2018-06-30 | 0.37 | 0.00 | 0.30 |
| 2018-03-31 | -0.08 | 0.00 | 0.19 |
| 2017-12-31 | 0.01 | 0.00 | 0.19 |
| 2017-09-30 | -0.24 | 0.00 | 0.21 |
| 2017-06-30 | -0.47 | 0.00 | 0.26 |
| 2017-03-31 | -0.59 | 0.00 | 0.31 |
| 2016-12-31 | -0.91 | 0.00 | 0.11 |
| 2015-12-31 | -1.00 | 0.00 |
- MediXall Group has no debt.
- MediXall Group has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- MediXall Group has less than a year of cash runway based on current free cash flow.
- MediXall Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 37.9% each year.
Financial health checks
We assess MediXall Group's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) MediXall Group has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
MDXL Dividends
What is MediXall Group's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
MediXall Group
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate MediXall Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate MediXall Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Global Healthcare Services Industry Average Dividend Yield | Market Cap Weighted Average of 15 Stocks | 1.1% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as MediXall Group has not reported any payouts.
- Unable to verify if MediXall Group's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess MediXall Group's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can MediXall Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) MediXall Group has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
MDXL Management
CEO
| COMPENSATION | $152,500 |
| AGE | 56 |
| TENURE AS CEO | 2.5 years |
CEO Bio
Mr. Neil Swartz, CPA, serves as the Chief Executive Officer at MediXall Group, Inc and served as its President. Mr. Swartz served as Interim Chief Executive Officer at MediXall Group, Inc since December 28, 2016 and served as its Interim President. Mr. Swartz has been the Interim Chief Executive Officer and Interim President at Continental Rail Corp. since December 28, 2016. Mr. Swartz has been the President of TurnKey Capital Inc. since March 14, 2016 and has been its Chief Executive Officer since October 31, 2014. Mr. Swartz has been President and Chief Executive Officer of Train Travel Holdings, Inc. (TBG Holdings Corp) since 2009 and serves as its Director. He serves as Chief Executive Officer of TBG Investment Partners, LLLP. He also serves as the Chairman and Chief Executive Officer of Monkey Rock Group, Inc. He is a Co-founder of Visiomed International, Inc. Mr. Swartz served as Chairman and Director of MediXall Group, Inc from July 29 to December 11 in 2013. Mr. Swartz served as the President, Chief Executive Officer and Director of TurnKey Capital Inc. from January 23, 2014 to October 3, 2014. Mr. Swartz's business experience includes positions such as managing director of Sunbelt South East Florida, LLC, a business brokerage of mergers and acquisitions firm with 350 offices worldwide. Prior to TBG and Sunbelt, Mr. Swartz was Chairman and Chief Executive Officer of a software company, which he took public on the NASDAQ Small Cap Market. He served as Chief Executive Officer and Director of NetSpace International Holdings, Inc. until August 2007. He served as Chief Financial Officer and Director of Kaya Holdings, Inc. until August 2011. He has been Chairman of the Board of Directors at MediXall Group, Inc. since May 9, 2018. He served as Chairman of Continental Rail Corp. since July 29, 2013 until December 11, 2013. He serves as Director of TurnKey Capital Inc. He served as a Director of TurnKey Capital Inc. since October 31, 2014 until January 15, 2016. Mr. Swartz is a CPA and received his BS degree in Accounting from Northeastern University. He is a member of the American Institute of Certified Public Accountants and the Pennsylvania Institute of Certified Public Accountants.
CEO Compensation
- Neil's compensation has been consistent with company performance over the past year, both up more than 20%.
- Neil's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the MediXall Group management team in years:
- The tenure for the MediXall Group management team is about average.
Management Team
Neil Swartz
Chairman & CEO
$153K
56
2.5 yrs
Tim Hart
CFO, Treasurer
$293K
59
6.5 yrs
Michael Swartz
President
26
Guy Connor
Executive Vice President
56
John Howard
Senior Vice President of Laboratory Services
0.5 yrs
Board of Directors Tenure
Average tenure and age of the MediXall Group board of directors in years:
- The average tenure for the MediXall Group board of directors is less than 3 years, this suggests a new board.
Board of Directors
Tim Hart
CFO, Treasurer
$293K
59
6.5 yrs
Noel Guillama-Alvarez
Director
59
2.5 yrs
Neil Swartz
Chairman & CEO
$153K
56
1.1 yrs
Winston Marshall
Member of Medical Advisory Board
53
1.3 yrs
John DeLuca
Member of Medical Advisory Board
1.3 yrs
Kenneth Janson
Member of Medical Advisory Board
1.3 yrs
Christopher Metzler
Non-Executive Director
1.1 yrs
Benjamin Frosch
Member of Strategic Advisory Board
0.8 yrs
Steven Gass
Member of Strategic Advisory Board
0.8 yrs
Ned Siegel
Non-Executive Director
66
0.7 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess MediXall Group's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) MediXall Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
MDXL Company Info
Description
MediXall Group, Inc. operates as a healthcare incubator for development-stage healthcare technology companies in the United States. The company operates an electronic healthcare platform, where patients/clients can shop for their own medical services; diagnostic procedures and services; and medical equipment and devices to consumers and corporations, such as self-insured and private insurance companies. It also provides medical procedure, cosmetic and elective procedure, commercial, and medical accounts receivable loans to the healthcare sector. MediXall Group, Inc. is based in Fort Lauderdale, Florida.
Details
| Name: | MediXall Group, Inc. |
| MDXL | |
| Exchange: | OTCPK |
| Founded: | |
| $153,333,713 | |
| 73,016,054 | |
| Website: | http://www.medixall.com |
| Address: |
MediXall Group, Inc. 2929 East Commercial Boulevard, Suite PH-D, Fort Lauderdale, Florida, 33308, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| OTCPK | MDXL | Common Stock | Pink Sheets LLC | US | USD | 14. Dec 2016 |
Number of employees
Current staff
Industry
| Health Care Technology | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/16 00:51 |
| End of day share price update: | 2019/06/10 00:00 |
| Last earnings filing: | 2019/05/30 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
